RxFINE-Low trial opens recruiting for breast cancer treatment comparison — LiveFuture News
Open on LiveFuture.ai →

RxFINE-Low trial opens recruiting for breast cancer treatment comparison

The RxFINE-Low Trial is now recruiting in PHASE3, comparing chemotherapy plus hormone therapy plus ribociclib with hormone therapy plus ribociclib alone for high anatomic stage breast cancer with low recurrence risk.

A new PHASE3 study on breast cancer treatment is recruiting now, and the practical question is straightforward: can hormone therapy with ribociclib do as well as a path that starts with chemotherapy and then adds hormone therapy with ribociclib? The RxFINE-Low Trial is listed on ClinicalTrials.gov as RECRUITING, with no results posted yet and an estimated primary completion date of 2029-07-31.

For people following treatment options, that makes this a live comparison rather than a finished answer. The study is focused on high anatomic stage breast cancer with low recurrence risk, so the result could speak to how doctors think about intensity, convenience, and balance of treatment steps in this setting.

"This record describes a study and its registry status; study outcomes require posted results." — ctgov_v2

How the trial is set up

The study is RANDOMIZED, which means participants are assigned to one of two groups by chance. Arm A is chemotherapy, hormone therapy, ribociclib, while Arm B is hormone therapy, ribociclib.

Several named interventions appear in both arms, including Anastrozole, Biospecimen Collection, Bone Scan, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, and Ribociclib Succinate. Chemotherapy appears only in Arm A, which is the clearest difference in the comparison being tested.

"The primary analysis will compare treatment groups defined by the randomized treatment assignment (intent-to-treat analysis)." — native_source_facts

What the study will measure

The main outcome is Invasive breast cancer-free survival (iBCFS), measured from randomization to invasive disease or death, up to 10 years. The description defines invasive disease to include local invasive recurrence after mastectomy, local invasive recurrence in the ipsilateral breast after lumpectomy, regional recurrence, distant recurrence, or contralateral invasive breast cancer.

That means the trial is not only asking whether one treatment path is easier or lighter, but whether it keeps people free from invasive breast cancer events over time. The record also notes a secondary per protocol analysis, which looks at groups defined by treatment received.

"Invasive disease defined as the first occurrence of one of the following events: local invasive recurrence following mastectomy, local invasive recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, or contralateral invasive breast cancer." — native_sour

Why it sits within Cancer Breakthroughs

This study is one of several cancer-related registry observations connected to the active Cancer Breakthroughs special event. Within that set, it sits alongside other recruiting studies in breast cancer and other cancers, including ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy.

Read together, the linked studies suggest an active year for trial starts and registry updates, but each one still stands on its own. For RxFINE-Low, the key point is simple: it is open, it is comparing two treatment approaches, and the question it asks will stay open until results are posted.